一种基于多参数MRI识别高风险代谢功能障碍相关脂肪性肝炎的新模型
前瞻性纳入118例肝脂肪变且伴代谢危险因素的患者,其中80例为高风险MASH,行MRE、T1 mapping及化学位移编码MRI测量PDFF与R2*后行肝活检。基于MRE、PDFF和T1构建的EFT1模型在训练集和测试集AUC均为0.995,最佳截断值-0.431时敏感度98.2%/95.7%、特异度96.3%/100%,优于FIB-4、APRI、GPR,与MAST评分相当。
要点
- EFT1模型联合MRE、PDFF和T1 mapping,识别高风险MASH的AUC达0.995。
- 最佳截断值-0.431时,训练集敏感度98.2%、特异度96.3%,测试集敏感度95.7%、特异度100%。
- EFT1诊断效能优于FIB-4、APRI和GPR,与MAST评分相当。
核心结论
- 新型EFT1模型在无创识别高风险MASH方面表现出合理性能,在敏感度与特异度之间取得适当平衡。
研究设计与样本
- 前瞻性研究纳入118例肝脂肪变且伴代谢危险因素的患者(55例男性,年龄48±13岁),其中80例为高风险MASH;行MRE、T1 mapping、化学位移编码MRI测量PDFF和R2*后行肝活检;按70%训练集、30%测试集建模与验证。
关键影像表现/征象
- 高风险MASH组与非高风险MASH组之间MRE、PDFF和T1均存在显著差异。
诊断标准与关键数值
- EFT1模型联合MRE、PDFF和T1,训练集AUC 0.995(95%CI 0.985-1.000),测试集AUC 0.995(95%CI 0.979-1.000)。
- 最佳截断值-0.431时,训练集敏感度98.2%、特异度96.3%,测试集敏感度95.7%、特异度100%。
- EFT1诊断效能优于传统评分系统FIB-4、APRI和GPR,与MAST评分相当。
临床应用与阅片要点
- 作者认为EFT1模型为高风险MASH的早期识别提供了高准确度的无创工具,有助于及时干预和个体化治疗策略,可能减少疾病进展并改善患者结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To develop and evaluate a novel multi-parameter MRI-based model (EFT1) for identifying high-risk metabolic dysfunction-associated steatohepatitis (MASH) to improve diagnostic accuracy and efficiency.
MATERIALS AND METHODS: A prospective study included 118 patients (55 male; 48 ± 13 years) with hepatic steatosis and metabolic risk factors. Among these, 80 patients were classified as having high-risk MASH. Magnetic resonance elastography (MRE), T1 mapping, chemical-shift encoded MRI for quantification of proton density fat fraction (PDFF) and R2* were performed, followed by liver biopsy. MRI parameters were analyzed and correlated with histological features. The EFT1 model was developed using logistic regression and full subset regression analysis on a training cohort (70%) and validated on a test cohort (30%). The performance of the model was compared with traditional scoring systems.
RESULTS: Significant differences were observed in MRE, PDFF, and T1 between high-risk MASH and non-high-risk MASH groups. The EFT1 model, combining MRE, PDFF, and T1 showed strong diagnostic performance in both training (AUC 0.995, 95% CI 0.985-1.000) and test cohorts (AUC 0.995, 95% CI 0.979-1.000). At the optimal cut-off value of -0.431, the model achieved high sensitivity (98.2% training, 95.7% test) and specificity (96.3% training, 100% test). The EFT1 model outperformed traditional scoring systems (FIB-4, APRI, GPR) and showed comparable performance to the MAST score in identifying high-risk MASH.
CONCLUSION: The novel EFT1 model demonstrates reasonable performance in non-invasive identification of high-risk MASH patients compared to other models, achieving an appropriate balance between sensitivity and specificity.
CLINICAL TRIAL REGISTRATION: This study is registered with Chictr.org.cn (ChiCTR2400094017).
KEY POINTS: Question Current non-invasive scoring systems for high-risk MASH have limitations. A novel multi-parameter MRI-based model is proposed to improve diagnostic accuracy and efficiency. Findings A novel multi-parameter MRI-based model (EFT1), incorporating MRE, PDFF, and T1 mapping, demonstrated higher accuracy in identifying high-risk MASH with an AUC of 0.995. Clinical relevance The EFT1 model provides a highly accurate, non-invasive tool for early identification of high-risk MASH, facilitating timely intervention and personalized treatment strategies, potentially reducing disease progression and improving patient outcomes.
引用
- Ma W, Huang X, Feng Z, et al. A novel multi-parameter MRI-based model for identification of high-risk metabolic dysfunction-associated steatohepatitis. Eur Radiol. 2025. PMID: 40839133. doi:10.1007/s00330-025-11944-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。